Background. We investigated in vitro whether HLA highly sensitized patients with end-stage renal disease will be disadvantaged immunologically after a genetically engineered pig kidney transplant. Methods. Blood was drawn from patients with a calculated panel-reactive antibody (cPRA) 99% to 100% (Gp1, n = 10) or cPRA 0% (Gp2, n = 12), and from healthy volunteers (Gp3, n = 10). Serum IgM and IgG binding was measured (i) to galactose-α1-3 galactose and N-glycolylneuraminic acid glycans by enzyme-linked immunosorbent assay, and (ii) to pig red blood cell, pig aortic endothelial cells, and pig peripheral blood mononuclear cell from α1,3-galactosyltransferase gene-knockout (GTKO)/CD46 and GTKO/CD46/cytidine monophosphate-N-acetylneuraminic acid hydroxylase-knockout (CMAHKO) pigs by flow cytometry. (iii) T-cell and B-cell phenotypes were determined by flow cytometry, and (iv) proliferation of T-cell and B-cell carboxyfluorescein diacetate succinimidyl ester-mixed lymphocyte reaction. Results. (i) By enzyme-linked immunosorbent assay, there was no difference in IgM or IgG binding to galactose-α1-3 galactose or N-glycolylneuraminic acid between Gps1 and 2, but binding was significantly reduced in both groups compared to Gp3. (ii) IgM and IgG binding in Gps1 and 2 was also significantly lower to GTKO/CD46 pig cells than in healthy controls, but there were no differences between the 3 groups in binding to GTKO/CD46/CMAHKO cells. (iii and iv) Gp1 patients had more memory T cells than Gp2, but there was no difference in T or B cell proliferation when stimulated by any pig cells. The proliferative responses in all 3 groups were weakest when stimulated by GTKO/CD46/CMAHKO pig peripheral blood mononuclear cell. 
K
idney transplantation is the preferred treatment for most patients with end-stage renal disease (ESRD). [1] [2] [3] Patients highly sensitized to HLAs, with a high level of calculated panel-reactive antibodies (cPRA), are unlikely to receive a human organ in a timely manner. [4] [5] [6] [7] Those with a cPRA of 99% to 100% may never receive an allograft. 8, 9 Pigs could provide an unlimited source of kidneys. With the development of genetic-engineering, the 3 well-characterized glycan xenoantigens on pig cells (galactose-α1-3 galactose [Gal] , N-glycolylneuraminic acid [Neu5Gc] , and Sda, a product of beta-1,4-N-acety1-galactosaminyltransferase 2 (β4GalNT2), to be deleted by knockout (KO) technology. 10, 11 Pigs can also be manipulated to express 1 or more human complementor coagulation-regulatory proteins, providing additional protection against antibody-mediated rejection. [12] [13] [14] Some previous in vitro studies have indicated that HLA-sensitized patients will not be at greater risk of humoral rejection of a pig organ than HLA nonsensitized patients. [15] [16] [17] [18] However, other studies suggest some cross-reactivity between anti-HLA and anti-swine leukocyte antigen (SLA) antibodies. [19] [20] [21] [22] [23] [24] Patients with both anti-HLA class I and II antibodies may exhibit increased T-cell responses to pig cells, 25 though others found that HLA sensitization was not indicative of a heightened T-cell response to SLA. 26 Our present study investigated the impact of (i) cPRA, and (ii) T-cell and B-cell reactivity to pig cells in HLA highly sensitized (cPRA 99-100%) and nonsensitized (cPRA 0%) prospective kidney transplant recipients.
We compared serum IgM and IgG binding from patients with high cPRA with those with a negative cPRA against red blood cells (RBCs), aortic endothelial cells (AECs), and peripheral blood mononuclear cells (PBMCs) from (i) α1, 3-galactosyltransferase gene knockout (GTKO) pigs that express the human complement-regulatory protein, CD46, or (ii) GTKO/CD46 pigs in which expression of Neu5Gc had been deleted by KO of the gene for cytidine-monophosphate-N-acetylneuraminic acid hydroxylase (GTKO/CD46/CMAHKO pigs) (RBCs express only glycan antigens, but not SLA class I or class II, whereas AECs and PBMCs express both glycan antigens and SLA.) We also compared the phenotype frequencies and proliferative responses of T or B cells to wildtype (WT, ie, genetically unmodified), GTKO/CD46, and GTKO/CD46/CMAHKO pig cells.
Our study indicated that a patient with a high cPRA should accept a kidney from a genetically engineered pig with no increased immune risk when compared to a nonsensitized patient (or any healthy human). These data differ from some other studies, and the possible reasons are discussed.
METHODS Human Serum and Cell Samples
All studies using human blood were approved by the Research Ethics Committee of the University of Pittsburgh (IRB REN16040230). Blood (40 mL) was drawn on a single occasion from 22 subjects awaiting kidney transplantation and from 10 human volunteers.
Group 1 (n = 10) consisted of patients awaiting kidney allotransplantation who had a high cPRA (99-100%); all had undergone previous kidney transplantation. Group 2 (n = 12) were patients with a negative cPRA (0%); none had undergone a previous kidney transplant. Group 3 (n = 10) were healthy human volunteers (controls). The cPRA was not assessed in the group 3 subjects, but none had a history suggesting previous HLA or SLA exposure.
All group 1/2 subjects had been on hemodialysis and had received no exogenous immunosuppressive therapy for less than 5 years, and were not selected by age, gender, ethnicity, or cause of ESRD.
Human (h) PBMCs from groups 1 to 3 subjects were isolated from fresh blood samples. 27 
Pig Cell Sources and Preparation of RBCs, AECs, and PBMCs
The RBCs, AECs, and PBMCs were collected from (i) wildtype (WT), (ii) GTKO/CD46, and (iii) GTKO/CD46/CMAHKO pigs (Revivicor, Blacksburg, VA). Binding of antibodies to GTKO/CD46 and GTKO/CD46/ CMAHKO pig cells was measured by flow cytometry using relative median fluorescence intensity (RMFI). 29 
Measurement of T-Cell and B-Cell Frequency and Phenotypes in hPBMC
Surface staining of PBMCs from the human subjects was performed by flow cytometry (see Supplementary Methods).
Measurement of Human T-Cell and B-Cell Proliferative Responses to pPBMC by Flow Cytometry
For carboxyfluorescein diacetate succinimidyl ester-mixed lymphocyte reaction (CFSE-MLR), human PBMCs were used as responder cells, with stimulator cells (pPBMC) from WT, GTKO/CD46, or GTKO/CD46/CMAHKO pigs. 30 
Statistical Analysis
Normally distributed data are presented as mean and SD. Study groups were compared using Student t test (for normally distributed continuous variables) or nonparametric Mann-Whitney test (for not normally distributed variables) to determine statistical significance. For correlation, a Pearson correlation test was used. A P value less than 0.05 was considered significant.
RESULTS

Antibody Studies
Quantitation of Total Immunoglobulins in Human Sera
Total IgA, IgE, IgG, and IgM levels in serum from all subjects were compared ( Figure 1 ; Table S1 , SDC, http://links. lww.com/TP/B518). Total IgA in group 1 was higher than in both groups 2 and 3 (P < 0.05 and P < 0.005, respectively). There was no difference in total IgE levels between the 3 groups. Group 1 had significantly higher levels of IgG and IgM than group 2 (P < 0.05), but no difference from group 3. There were no significant differences in IgA, IgE, and IgG between groups 2 and 3, but the level of IgM in group 2 was significantly lower than in group 3 (P < 0.01).
These data suggest that hemodialysis (in groups 1/2) does not reduce the total immunoglobulin levels compared to healthy control subjects (group 3). However, there was evidence that ESRD patients with a high cPRA had higher levels of total IgA, IgG, and IgM than patients with a negative cPRA, but only IgA was higher than that in the healthy controls.
Human IgM and IgG Binding to Synthetic Glycans by ELISA
The high (group 1) and the negative (group 2) cPRA patients exhibited no significant differences in IgM or IgG binding to either Gal or Neu5Gc ( Figure 2 ). The control group 3, however, had significantly higher IgM and IgG binding to both glycans than either study group (P < 0.005 for IgM, P < 0.05 for IgG). Thus, the binding of human IgM or IgG to these glycans did not correlate with the level of human antibodies directed to HLA.
In contrast to total immunoglobulin levels, these data strongly suggest that chronic hemodialysis or the presence of ESRD results in reduced antiglycan immunoglobulin levels in patients awaiting kidney transplantation (discussed below). FIGURE 1. The amount of total IgA, IgE, IgG, IgM antibodies in all subjects was measured in high cPRA subjects (group 1, n = 10), in negative cPRA subjects (group 2, n = 12), and healthy volunteers (controls, group 3, n = 10) (ns = not significant; *P < 0.05). Only 1 patient (in group 2) had an IgA nephropathy (a high anti-HLA IgA has been associated with less rejection by binding IgG antibodies, [31] [32] [33] [34] and a correlation of increased IgA levels with chronic kidney disease has been noted in the past 35 ).
FIGURE 2. Anti-Gal and anti-Neu5Gc IgM/IgG were measured by ELISA in high cPRA subjects (group 1, n = 10), in negative cPRA subjects (group 2, n = 12), and in healthy controls (group 3, n = 10) (ns = not significant; *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001).
Human IgM and IgG Binding to GTKO/CD46 and GTKO/CD46/CMAHKO Pig Cells by Flow Cytometry
Binding to GTKO/CD46 Pig Cells
In patients with high or negative cPRA, there was a very low level of IgM binding to all of the 3 types of cells from GTKO/ CD46 pigs, and almost no binding of IgG (Figures 3A-C;  Table S2 , SDC, http://links.lww.com/TP/B518), with no significant difference in binding of either IgM or IgG between groups 1 and 2. Binding of IgM and IgG in group 3 was significantly higher. These data correlate with the results of ELISA.
Binding to GTKO/CD46/CMAHKO Pig Cells
There was no significant difference in IgM/IgG binding to all 3 types of cells from GTKO/CD46/CMAHKO pigs among the 3 groups (Figures 3A-C) . The only exception was that IgG in the high cPRA group showed more binding to pAEC than the negative cPRA group (P < 0.01) ( Figure 3B ). IgG binding in group 3 sera was higher than in the group 2 sera (Figure 3B ), though the binding in all 3 groups was very low. These data indicate that the level of human IgM/IgG binding to GTKO/CD46/CMAHKO pig cells did not correlate with cPRA status.
Healthy controls had higher IgM (P < 0.05) and IgG (P < 0.005) antibody binding to pig (p)RBC and pPBMC from GTKO/CD46 pigs ( Figures 3A, C) . This contrasted to the near absence of antibody binding (IgM and IgG) in healthy controls to all cell targets from GTKO/CD46/CMAHKO pigs. Absence of Neu5Gc expression, therefore, significantly reduced binding of healthy human sera to all pig cells tested ( Figure 3D ), but not binding of sera of patients with ESRD undergoing hemodialysis.
Whereas binding of both IgM and IgG from sera in group 3 to GTKO/CD46/CMAHKO pig cells was always reduced compared to binding to GTKO/CD46 pig cells, this was not always the case in sera from groups 1/2 ( Figure 3D ). Although IgM binding in sera from groups 1/2 was always reduced (or unchanged) to GTKO/CD46/CMAHKO cells (compared with GTKO/CD46 cells), IgG binding was sometimes minimally increased (<15%) (P < 0.005 for both high and negative cPRA IgG binding to pPBMCs, P < 0.05 for high cPRA IgG binding to pAECs), although the level of binding was always low.
These data suggest that many healthy subject sera (group 3) have antibodies that bind to Neu5Gc, whereas sera from many ESRD patients on hemodialysis (groups 1/2) do not. The observation that in some ESRD patients IgG binding was sometimes increased to GTKO/CD46/CMAHKO pAECs and pPBMCs (but not to pRBCs) suggests that the binding may have been to nonglycan antigens, for example, SLA.
In the flow cytometry studies ( Figures 3A-C) , there were occasional patients in groups 1/2 with aberrantly higher levels of IgM or IgG binding to GTKO/hCD46 pig cells. However, these occasional patients did not necessarily have a greater number of memory T cells or a greater than average T cell proliferative response.
Cellular Studies
Phenotypes and Quantitation of T and B Cells in hPBMCs by Flow Cytometry
One representative flow gating strategy in a high cPRA subject to analyze the phenotypes and quantitation of T and B cells is shown in Figure 4A .
There was no significant difference in the frequency of CD3 + T cells among the 3 groups ( Figure 4B , Table S3 , SDC, http://links.lww.com/TP/B518). However, there was a higher frequency of CD4 + T cells in group 2 compared with group 1 (P < 0.05) and group 3 (P < 0.01), whereas there was no significant difference between groups 1 and 3. Even though group 3 had a higher frequency of CD8 + T cells than group 2 (P < 0.05), there was no significant difference between groups 1 and 3 or between groups 1 and 2.
CD3 + T Cell Subsets
T N cells were less frequent in group 2 than in group 3 (P < 0.05), whereas there was no significant difference between groups 1 and 2 ( Figure 4C ). There was no significant difference in frequency of T CM cells among the 3 groups. Group 1 had the highest frequency of T EM RA cells (P < 0.05). No differences in T EM numbers were observed.
CD4 + T Cells
There were no significant differences in the frequencies of T N, T EM and T EM RA of CD4 + T cells among the 3 groups ( Figure 4D , Table S3 , SDC, http://links.lww.com/TP/B518). However, groups 1 and 2 had significantly higher T CM cell numbers than group 3 (P < 0.05), but there was no significant difference between groups 1 and 2.
CD8 + T Cells
There were no differences in T N and TEM between the groups ( Figure 4E , Table S3 , SDC, http://links.lww.com/TP/ B518). Group 1 had the highest frequency of T EM RA cells within the CD8 + T cell population, but had a lower frequency of T CM cells.
As with IgM binding to GTKO/CD46 cells, there were occasional "outliers" (with a higher percentage of a specific cell type) in the group 1/2 populations, suggesting that these subjects might have a stronger T-cell proliferative response to pig antigens. However, patients with a higher percentage of a specific T memory cell did not necessarily have a stronger T-cell proliferative response.
CD20 + B Cells
The frequency of CD20 + B cells in group 1 was significantly lower than in group 3 (P < 0.05), but not different from group 2 ( Figure 4B ). Moreover, there was no significant difference in B cell subsets among the 3 groups ( Figure 4F , Table S3 , SDC, http://links.lww.com/TP/B518).
Human T and B Cell Proliferation in Response to pPBMCs (by CFSE-MLR)
Dot-plot representative of the proliferation of CD3 + , CD4 + , CD8 + T cells, and CD20 + cells in hPBMC of 1 high cPRA subject responding to pPBMC from WT, GTKO/CD46, and GTKOCD46/CMAHKO is shown in Figure 5A ) in high cPRA subjects (group 1, n = 10), in negative cPRA subjects (group 2, n = 12), and healthy controls (group 3, n = 10). (D) The impact of pig genetics on IgM/IgG binding to pRBC, pAEC, and pPBMC (ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001).
These data suggest that the human T cell proliferative response to pPBMCs is not affected by the cPRA, but is influenced by the type of pig stimulator cells. High cPRA patients did not have a T-cell proliferative response that was stronger than patients with a negative cPRA (not shown).
The B cell (CD20 + ) proliferative response showed very few differences between the 3 human groups, nor was there a great difference in response to the 3 pig cell types (Figures 5A, B) .
Correlation Data
Correlation of IgM/IgG binding with T/B cell proliferation, and the ratio of T/B cell phenotypes with proliferation are reported in Supplementary Methods and Results.
DISCUSSION
In the United States, despite the new allocation rules, HLA highly sensitized patients remain disadvantaged in obtaining a renal allograft. We aimed to determine whether patients with a cPRA 99% to 100% would be disadvantaged if a pig xenograft was transplanted compared to those with a cPRA 0%. We also investigated whether high cPRA patients demonstrated differences in the T-cell and B-cell responses that might affect the outcome of a xenograft.
In concordance with previous studies, 29, 36 in healthy humans (group 3), we found significantly diminished antibody binding to GTKO/CD46/CMAHKO pig cells compared to GTKO/CD46 pig cells ( Figure 3D ). In the group 1/ 2 patients, IgM binding was also reduced to GTKO/CD46/ CMAHKO pig cells, but IgG binding was sometimes unchanged or even slightly increased. Importantly, there was no greater binding of IgM or IgG xenoreactive antibodies in the sera of high cPRA patients than negative cPRA patients. Double-KO pig cells (GTKO and CMAHKO) do not stimulate human responder cells more than in an allograft model, and the T-cell responses are similarly effectively reduced by conventional immunosuppressive agents. 11 In our current study, the antipig T-cell response, as measured by CFSE-MLR, was also significantly reduced compared with that in WT pig cells ( Figure 5 ). HLA highly sensitized patients did not have a stronger T-cell response to pig cells.
A previous study indicated that healthy adult blood contains comparable percentages of CD45RA − (T CM , T EM ), CD45RA + (T N , T EM RA), and CD4 + (T N , T CM, T EM ) cells (20-40%), whereas CD8 + T EM RA cells are seen in higher frequency than CD4 + T cells. 37 Our results in healthy humans (group 3) were comparable ( Figure 4 , Table S3 , SDC, http:// links.lww.com/TP/B518).
T EM RA cells (with the same function as T EM cells) are found mostly in peripheral inflamed tissues and can secrete effector molecules in response to antigens. 38 Our data show that, compared with the negative cPRA and healthy human groups, high cPRA patients had the highest frequency of T EM RA cells (among the total CD3
+ T cell population and in the CD8 + T cell subset, but not in the CD4 + T cell subset) ( Figures 4C, D, E) . This might be associated with previous exposure to alloantigens. Our study supports the conclusion that human subjects with a high level of sensitization would not react immunologically to DKO (or presumably triple-KO) donor pig cells any more strongly than patients with a negative cPRA (as measured by antibody binding). Furthermore, their T-cell responses would not be stronger than that in patients with a negative cPRA.
Our observation that patients awaiting kidney allotransplantation (whether with a high or negative cPRA) had significantly lower levels of anti-Gal and anti-Neu5Gc antibodies (but not of total immunoglobulin) than healthy controls does not appear to be reported previously. It is unlikely that hemodialysis directly removes antibodies since standard hemodialysis filters typically have a cutoff between 10 and 20 kDa, whereas an IgG molecule is about 150 kDa, and is thus not removed by hemodialysis. 39 It is well recognized that ESRD patients are to some extent immunocompromised and are more susceptible to infections. [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] The clinical impact of ESRD on antipig immunity remains largely unknown. However, in the present study, we did not document major differences in T-cell and B-cell proliferation compared with healthy humans. The profound reduction in antibody levels to pig glycan antigens, however, was surprising, particularly as total immunoglobulin levels remained within the normal ranges.
Before 2004, studies of human antipig responses were limited by not having access to GTKO pigs. However, in 1998, 2 studies examined the reactivity of sera from HLA highly sensitized and nonsensitized patients. 19, 52 Taylor et al 52 adsorbed natural antiglycan antibodies on WT pRBCs (and on pooled human platelets) and found a decrease of reactivity in the nonsensitized patients, but not in the highly sensitized patients, leading them to conclude that some reactivity was due to anti-HLA class I-specific antibodies (presumably crossreacting to SLA). Naziruddin et al and Varela et al 19, 22 independently came to similar conclusions. Barreau et al 20 used pig kidneys to adsorb xenoreactive antibodies from sera of HLA highly sensitized patients. Eluted antibodies from the pig kidneys were mostly anti-Gal, but some anti-HLA class I antibodies were also detected. In 2002, Taylor's group reported that sera (adsorbed as above) from HLA-sensitized patients (cPRA >64%) demonstrated a positive crossmatch against CD55 (hDAF)-transgenic pig leukocytes, again indicating that some anti-HLA antibodies might cross-react with SLA. 21 Cross-reactivity between HLA and SLA was studied by Mulder et al, 23 who tested the binding of 68 human anti-HLA monoclonal antibodies to haploidentical inbred miniature swine PBMCs. Of the 68 anti-HLA monoclonal antibodies, 9 were reactive to pig cells, and 4 of these were specific to the 65QIS epitope on the SLA α-helix.
The availability of GTKO pigs was a breakthrough in xenotransplantation research [53] [54] [55] by greatly reducing human , and CD8 + Tcells, and B cells in high cPRA subjects (n = 10), negative cPRA subjects (n = 12), and healthy controls (n = 9) were determined by flow cytometry. Naive and memory (C) CD3 + T cell, (D) CD4 + T cell, and (E) CD8 + T cell populations present in hPBMC from subjects in the 3 study groups were identified and quantified (presented as percentage of total CD3 + T cells, CD4 + T cells, and CD8 + T cells, respectively) by flow cytometry. F, The ratios of B cell phenotypes in each hPBMC sample of all study groups were identified and quantified (presented as percentage of total CD20 + B cells) by flow cytometry. (n = 10 for high cPRA subjects, n = 12 for negative cPRA subjects, and n = 9 for healthy controls, ns = not significant; *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001). serum antibody binding to pig cells, 16, 56 and reducing antibody-mediated injury to pig organs. [57] [58] [59] By 2006, 2 groups had studied antibody binding to cells from 2 different GTKO pigs with sera from patients awaiting kidney transplantation. 16, 17 Both studies showed that sera from HLA highly sensitized patients showed no greater binding to GTKO pig cells than nonsensitized sera.
Interestingly, a reduced level of anti-pig antibody in patients with ESRD was not reported in any of these studies.
Investigators have identified 2 other glycans that are targets for human antipig antibodies. [60] [61] [62] These are Neu5Gc and Sda, suggesting that KO of CMAH (coding for Neu5Gc) and of β4GalNT2 (coding for Sda) in GTKO pig cells would reduce antibody binding further. This proved to be the case when investigators showed that human serum antibodies bound less to double-KO (lacking Gal and Sda or Gal and Neu5Gc) and triple-KO (lacking Gal, Neu5Gc, and Sda) pig cells than to WT or GTKO cells. 63, 64 In 2016, this group studied sera from 820 waitlisted patients using triple-KO pig cells. 24 Their conclusion was that, if all anti-pig glycan antibodies have been removed from the serum or no longer bind to the genetically engineered pig cells, some patients can be demonstrated to have anti-SLA class I antibodies.
Some investigators therefore demonstrated a potential increased risk of rejecting a pig graft in HLA highly sensitized patients (through cross-reactivity between anti-HLA and anti-SLA antibodies), but others did not. It is possible that these varying results are associated with differences in the SLA phenotype of the pigs from which the cells were derived. For example, there is convincing evidence that antibodies to certain HLA cross-react with specific SLA expressed in the pigs that 1 group has used for its studies (where the SLA type of the pigs is known). 24 However, there has been no definite evidence for such cross-reactivity in studies using pigs from other sources. Wong used the Massachusetts General Hospital SLA-well-defined inbred miniature swine as sources of cells, 17 and Hara used the Revivicor pigs, which were also those used in the present study (in which the SLA typing is unknown). 16 We suggest that SLA may be expressed in some pigs against which specific HLA-reactive antibodies may be directed, but not in other pigs. This important point needs to be clarified before clinical trials can be considered in patients with a high cPRA.
Another potential reason is that, in the present study, the target pig cells still expressed one of the known glycans, Sda, and antibody binding to Sda might have "masked" the binding to other antigens, for example, SLA. However, this would suggest that binding to SLA is low.
A third possibility may be the differences in the number of sera tested, which was far higher (n = 820) in the Martens study. 24 In this study, in a subset of patients with cPRA >80% (n = 119), in which sera were depleted with WT pRBCs, only 13 samples contained SLA class I-specific IgG, thus demonstrating that some sensitized patients (but by no means all) may demonstrate cross-reactivity.
A fourth possibility is that the immunosuppressed state in ESRD patients reduces the production of antibodies to a point where it is difficult to identify anti-SLA antibodies, the incidence and avidity of which are low. However, this would not account for their identification in some studies, but not in others, as presumably all ESRD patients are relatively equally immunocompromised.
The present study, and most others, indicates that there are at least some ESRD patients with a high cPRA who would appear to be at no greater risk of undergoing pig organ transplantation than patients with a negative cPRA. Furthermore, when antibodies are present that cross-react with a specific SLA, it should be possible by genetic engineering of the pig to delete the offending antigen(s). 65 
